Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experienceYasuhiro Oki, Jason R. Westin, Michael Wang et al.|British Journal of Haematology|2014Cited by 364
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan Fowler, Sattva S. Neelapu, R. Eric Davis et al.|The Lancet Oncology|2014Cited by 263
Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin LymphomaChelsea C. Pinnix, Bouthaina S. Dabaja, Grace L. Smith et al.|International Journal of Radiation Oncology*Biology*Physics|2015Cited by 132
The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphomaDai Chihara, Yasuhiro Oki, Michelle A. Fanale et al.|British Journal of Haematology|2016Cited by 118
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<scp>MCL</scp>) ‐ outcomes and mutation profile from venetoclax resistant <scp>MCL</scp> patientsShuangtao Zhao, Preetesh Jain, Rashmi Kanagal‐Shamanna et al.|American Journal of Hematology|2020Cited by 84